α-sarcoglycan CRISPR/Cas9 KO Plasmid (m): sc-422904
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- α-sarcoglycan CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the α-sarcoglycan genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: α-sarcoglycan Antibody (D-7): sc-271321
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
α-sarcoglycan CRISPR/Cas9 KO Plasmid (m) | sc-422904 | 20 µg | $397.00 |
Overview
Sgca encodes α-sarcoglycan, a core transmembrane component of the sarcoglycan complex within the dystrophin–glycoprotein complex that stabilizes the sarcolemma and supports force transmission in skeletal and cardiac muscle. By linking the extracellular matrix to the cytoskeleton, α-sarcoglycan contributes to membrane integrity and mechanotransduction during contraction and protects myofibers from contraction-induced damage. Disruption of Sgca perturbs dystrophin-associated protein complex assembly and compromises muscle fiber stability, providing a molecular basis for muscular dystrophy–like phenotypes in model systems. Mouse Sgca is therefore a key target for studying sarcolemmal adhesion signaling, muscle degeneration/regeneration programs, and downstream inflammatory and fibrotic remodeling pathways.
α-sarcoglycan CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Sgca gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Sgca together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Sgca open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish α-sarcoglycan protein expression.
This CRISPR knockout system enables efficient generation of Sgca-deficient cell models for investigation of α-sarcoglycan signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Sgca exon(s) critical for α-sarcoglycan function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Sgca genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by α-sarcoglycan CRISPR/Cas9 KO Plasmid (m) and α-sarcoglycan CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Sgca locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by α-sarcoglycan HDR Plasmid (m) and α-sarcoglycan HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Sgca homology arms to support homology-directed repair at defined Sgca target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.